Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

202 Results
Recruiting
Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
To make the T cells the investigators will take blood from the patient or from the previous bone marrow transplant donor and stimulate it with growth factors to make the …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Meclizine for Hepatocellular Carcinoma
The constitutive androstane receptor (CAR, NR1I3) is a nuclear receptor that plays a central role in hepatic detoxification of potentially toxic compounds, or xenobiotics. Chronic CAR activation by specific agonists …
Withdrawn
3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA
To prepare the neuroblastoma specific Natural Killer T cells (also called GINAKIT cells), about 80 mL (up to 6 tablespoons) of blood will be collected from the patient. For children, …
Baylor Role: Lead Sponsor
Recruiting
Ferric Citrate in ESRD Pilot Project
Iron deficiency anemia is very prevalent in end stage renal disease (ESRD) patients. Patients with ESRD require phosphate binders for hyperphosphatemia and erythropoiesis-stimulating agents (ESAs) and intravenous (IV) iron for …
Recruiting
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
To prepare the CD30.CAR T cells, research staff will take some blood from the subject. This would be drawn as two separate blood collections. Alternatively, if the subject's blood counts …
Baylor Role: Lead Sponsor
Completed
Fetal Hemoglobin Induction Treatment Metformin
This is a dose escalation, pilot study for subjects with sickle cell anemia (SCA) disease to determine if metformin has a beneficial effect on the treatment and quality of life …
Baylor Role: Lead Sponsor
Completed
Phase I/II Study OF Metformin in Combination With Cisplatin and Radiation in Head and Neck Squamous Cell Carcinoma
Information from laboratory studies and retrospective studies of patients with this disease has shown that the addition of metformin (a commonly used medicine for treating diabetes) to chemotherapy and radiation …
Baylor Role: Lead Sponsor
Active, Not Recruiting
Celecoxib With Chemotherapy in Localized, Muscle-Invasive Bladder Cancer
The purpose of this study is to compare patient tumor tissue before and after treatment with chemotherapy plus celecoxib. Investigators will look at gene expression, to see what effect celecoxib …
Baylor Role: Lead Sponsor
Recruiting
Mesenchymal Stromal Cells in Living Donor Kidney Transplantation
The study is a double-blind, randomized, controlled, dose-escalation and safety study of the investigational product, autologous MSCs, to be assessed for inducing immune suppression in living donor kidney transplant recipients …
Completed
High-Risk Neuroblastoma Chemotherapy Without G-CSF
Chemotherapy: CYCLE 1+2: Topotecan and cyclophosphamide Cycle 3+5: Cisplatin and Etoposide Cycle 4+6: Vincristine, Cyclophosphamide and Doxorubicin Stem cell collection: After the third cycle of chemotherapy, stem cells will be …
Baylor Role: Lead Sponsor